» Articles » PMID: 10196184

Altered Regulation of Cyclin G in Human Breast Cancer and Its Specific Localization at Replication Foci in Response to DNA Damage in P53+/+ Cells

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1999 Apr 10
PMID 10196184
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Cyclin G, a recent addition to the cyclin family, was initially identified in screens for new src kinase family members and soon thereafter by differential screening for transcriptional targets of the tumor suppressor gene, p53. We have identified cyclin G as being overexpressed in breast and prostate cancer cells using differential display polymerase chain reaction screening. We demonstrate here that cyclin G is overexpressed in human breast and prostate cancer cells and in cancer cells in situ from tumor specimens. Cyclin G expression was tightly regulated throughout the cell cycle in normal breast cells, peaking at the S and G2/M phases of the cell cycle with lower levels in G1. The cell cycle-dependent expression was absent in breast cancer cells. Following DNA damage in normal p53+/+ cells, cyclin G is triggered to cluster in discrete nuclear DNA replication foci that contain replication-associated proteins such as proliferating cell nuclear antigen (PCNA). While p53-/- cells displayed a faint cyclin G nuclear staining pattern, there was no increased expression and no change in distribution of the staining pattern after DNA damage. The specific subcellular localization of cyclin G at DNA replication foci provides an additional link between p53-mediated growth arrest and cell cycle regulation and suggests that cyclin G may act as an effector of p53-mediated events by functional association with replication foci protein(s).

Citing Articles

Deregulation of miR-27a may contribute to canine fibroblast activation after coculture with a mast cell tumour cell line.

Aguilera-Rojas M, Sharbati S, Stein T, Einspanier R FEBS Open Bio. 2020; 10(5):802-816.

PMID: 32133790 PMC: 7193169. DOI: 10.1002/2211-5463.12831.


Atypical cyclins: the extended family portrait.

Quandt E, Ribeiro M, Clotet J Cell Mol Life Sci. 2019; 77(2):231-242.

PMID: 31420702 PMC: 6971155. DOI: 10.1007/s00018-019-03262-7.


miR-23b suppresses lung carcinoma cell proliferation through CCNG1.

Han H, Zhang Z, Yang X, Yang W, Xue C, Cao X Oncol Lett. 2018; 16(4):4317-4324.

PMID: 30214567 PMC: 6126157. DOI: 10.3892/ol.2018.9181.


Cell cycle checkpoint control: The cyclin G1/Mdm2/p53 axis emerges as a strategic target for broad-spectrum cancer gene therapy - A review of molecular mechanisms for oncologists.

Gordon E, Ravicz J, Liu S, Chawla S, Hall F Mol Clin Oncol. 2018; 9(2):115-134.

PMID: 30101008 PMC: 6083405. DOI: 10.3892/mco.2018.1657.


HRPDviewer: human ribosome profiling data viewer.

Wu W, Jiang Y, Chang J, Chu Y, Chiu Y, Tsao Y Database (Oxford). 2018; 2018.

PMID: 30010738 PMC: 6041748. DOI: 10.1093/database/bay074.